873056-38-3

Usage

Uses

Used in Pharmaceutical Synthesis:
(5-Amino-2-(tert-butyl)phenyl)methanol is used as an intermediate for the synthesis of pharmaceuticals, contributing to the development of new drugs and medications. Its unique structure allows for the creation of a wide range of biologically active molecules, enhancing the therapeutic options available.
Used in Agrochemical Production:
In the agrochemical industry, (5-Amino-2-(tert-butyl)phenyl)methanol is utilized as a starting material for the production of various agrochemicals. Its role in the synthesis process helps develop compounds that can be used in the agricultural sector for pest control, crop protection, and other related applications.
Used in Organic Chemistry and Chemical Synthesis:
(5-Amino-2-(tert-butyl)phenyl)methanol is also used as a key component in the preparation of heterocycles, chiral ligands, and other complex organic compounds. Its versatile reactivity makes it a valuable asset in the field of organic chemistry, enabling the development of novel molecules with potential applications in various industries.

Upstream product

• 3282-56-2 4-tert-butylnitrobenzene 
• 6310-17-4 2-bromo-1-tert-butyl-4-nitrobenzene 
• 873056-28-1 2-(tert-butyl)-5-nitrobenzonitrile 
• 14034-90-3 2-tert-butyl-5-nitrobenzoic acid 
• 873056-34-9 methyl 2-tert-butyl-5-aminobenzoate 

Downstream Products

• 873050-23-8 N-(4-tert-butyl-3-(hydroxymethyl)phenyl)-4-oxo-1,4-dihydroquinoline-3-carboxamide 

Relevant academic research and scientific papers

Compositions for Treatment of Cystic Fibrosis and Other Chronic Diseases

The present invention relates to pharmaceutical compositions comprising an inhibitor of epithelial sodium channel activity in combination with at least one ABC Transporter modulator compound of Formula A, Formula B, Formula C, or Formula D. The invention also relates to pharmaceutical formulations thereof, and to methods of using such compositions in the treatment of CFTR mediated diseases, particularly cystic fibrosis using the pharmaceutical combination compositions.

Discovery of N -(2,4-Di- tert -butyl-5-hydroxyphenyl)-4-oxo-1,4-dihydroquinoline-3-carboxamide (VX-770, Ivacaftor), a potent and orally bioavailable CFTR potentiator

Quinolinone-3-carboxamide 1, a novel CFTR potentiator, was discovered using high-throughput screening in NIH-3T3 cells expressing the F508del-CFTR mutation. Extensive medicinal chemistry and iterative structure-activity relationship (SAR) studies to evaluate potency, selectivity, and pharmacokinetic properties resulted in the identification of N-(2,4-di-tert-butyl-5-hydroxyphenyl)-4-oxo-1,4-dihydroquinoline-3-carboxamide (VX-770, 48, ivacaftor), an investigational drug candidate approved by the FDA for the treatment of CF patients 6 years of age and older carrying the G551D mutation.

MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS

The present invention relates to modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator, compositions thereof, and methods therewith. The present invention also relates to methods of treating ABC transporter mediated diseases using such modulators.

COMPOSITIONS FOR TREATMENT OF CYSTIC FIBROSIS AND OTHER CHRONIC DISEASES

The present invention relates to pharmaceutical compositions comprising an inhibitor of epithelial sodium channel activity in combination with at least one ABC Transporter modulator compound of Formula A, Formula B, Formula C, or Formula D. The invention also relates to pharmaceutical formulations thereof, and to methods of using such compositions in the treatment of CFTR mediated diseases, particularly cystic fibrosis using the pharmaceutical combination compositions.